Evidence map›Paper›PMID 28929332›Full record

Trial reportInternational journal of hematology2018

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yoshihiro Hatta, Yasuhiko Miyata, Shinichi Kobayashi, Kensuke Usuki, Itaru Matsumura and 23 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Road to treatment-free remission in chronic myeloid leukemia.International journal of hematology · 2026
    Review
  13. Review
  14. Observational
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 1 country.

Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan. naotot@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-6758-3787
Tetsuzo TauchiDepartment of Hematology, Tokyo Medical University, Tokyo Medical University, Tokyo, Japan.
Kunio KitamuraDivision of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yoshio SaburiDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Yoshihiro HattaDivision of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Yasuhiko MiyataNational Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Shinichi KobayashiDivision of Hematology, National Defense Medical College, Tokorozawa, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Yosuke MinamiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Noriko UsuiDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Tetsuya FukudaDepartment of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Maho IshikawaDepartment of Hematology, Saitama Medical University International Medical Center, Saitama, Japan.
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Hiroshi GomyoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Osamu SasakiDepartment of Hematology, Miyagi Cancer Center, Natori, Japan.
Kohshi OhishiDepartment of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu, Japan.
Takaaki MiyakeDepartment of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.
Kiyotoshi ImaiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Hitoshi SuzushimaDepartment of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
Hideki MitsuiDepartment of Hematology, Otemae Hospital, Osaka, Japan.
Kazuto TogitaniDepartment of Hematology and Respiratory Medicine, Kochi Medical School, Kochi, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Shigeki OhtakeKanazawa University, Kanazawa, Japan.
Kazunori OhnishiJapanese Red Cross Aichi Blood Center, Seto, Japan.
Yukio KobayashiHematology Division, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University, Nagasaki, Japan.
Tomoki NaoeNational Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Japan Adult Leukemia Study Group
National Hospital Organization · JPFujisawa City Hospital · JPJikei University School of Medicine · JPKanazawa University · JPKochi Medical School Hospital · JPMiyagi Prefectural Hospital Organization · JPNihon University · JPNTT Medical Center · JPSapporo Hokuyu Hospital · JPTokyo Medical University · JPAkita University · JPChugoku Central Hospital · JPGunma Saiseikai Maebashi Hospital · JPIchinomiya Municipal City Hospital · JPJapanese Red Cross Society, Japan · JPMie University Hospital · JPMita Hospital · JPNagasaki University · JPNational Cancer Center Hospital East · JPOita Prefectural Hospital · JP

Funding

Japan Agency for Medical Research and Development 15ck0106189h0001Japan Agency for Medical Research and Development 16ck0106189h0002Japan Agency for Medical Research and Development 17ck0106189h0003
6 · The paper itself

Abstract

The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic myeloid leukemia (CML). CML patients who received imatinib treatment for at least 3 years and sustained deep molecular response for at least 2 years were eligible. Molecular recurrence was defined as loss of major molecular response (MMR). Of the 68 eligible patients, 38.2% were women, the median age was 55.0 years, and the median duration of imatinib treatment was 97.5 months. The 12-month TFR rate was 67.6%. Patients who lost MMR were immediately treated with imatinib again; all re-achieved MMR. Three-year treatment-free survival (TFS) was estimated as 64.6% using the Kaplan-Meier method. Undetectable molecular residual disease (UMRD) was defined as no BCR-ABL1 in > 100,000 ABL1 control genes using international scale polymerase chain reaction. UMRD at the study baseline was found to be predictive of continuation of TFR. Our findings suggest that CML patients who meet all the eligibility criteria that have commonly been used in the TFR trials are able to discontinue imatinib use safely. TFR may thus be valuable as a new goal for CML treatment in Japan.

Indexed as

Disease-Free SurvivalFemaleFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedProspective StudiesRemission InductionTreatment OutcomeBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImatinib MesylateBCR-ABL1Deep molecular responseImatinibTreatment-free remissionUndetectable molecular residual disease

Identifiers

PMID28929332
OpenAlexW2754183140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.